Loading clinical trials...
Loading clinical trials...
A Phase I Dose Escalation Study With 99mTC - or 186 Re-labelled Humanised Monoclonal Antibody BIWA 4, in Patients With Head and Neck Cancer
Conditions
Interventions
99mTc - labelled hMAb BIWA 4
186 Re - labelled hMAb BIWA 4
+3 more
Start Date
March 1, 1999
Primary Completion Date
June 1, 2001
Last Updated
July 30, 2014
NCT06998069
NCT06912087
NCT06303180
NCT05418842
NCT03914378
NCT06003231
Lead Sponsor
Boehringer Ingelheim
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions